Skip to main content
. 2017 Mar 21;8(22):36054–36066. doi: 10.18632/oncotarget.16425

Figure 1. Lapatinib upregulates ERRF expression in SK-BR-3 and BT-474 breast cancer cell lines, and higher levels of ERRF correlate with lapatinib sensitivities and better patient survival.

Figure 1

(A) Illustration of ERRF expression after lapatinib treatment (100 nM) for 12 and 24 hours in SK-BR-3 cells based on the data from the Array Express database [43]. (B, C) Lapatinib upregulates ERRF expression in BT-474 and SK-BR-3 breast cancer cell lines, both express ERRF and respond to ERBB2 inhibition. Lapatinib treatment was at the indicated concentrations (μM) for 48 hours, and ERRF expression was measured by real-time RT-PCR. (D) Row signal of ERRF in SK-BR3 and BT-474 breast cancer cell lines and lapatinib resistant clones derived from them, as detected in a microarray study in the GEO database [44]. (E) Correlation of ERRF mRNA levels with sensitivities to ERBB2 inhibition in breast cancer cell lines, according to published information [45] and the CCLE database [58]. (F) Higher levels of ERRF expression are associated with better prognosis in ERBB2-positive breast cancer, as determined in the BreastMark database (HR = 0.5442, p = 0.028, n = 107).